Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database

Albert Trinh-Duc 1 Agnès Lillo-Le Louët 2, 3 Éric Tellier 4 Thibault Viard 4 Grégoire Le Gal 5 David M Smadja 6, 7, 8, 9
1 AGEN - SAU - Service d'Accueil des Urgences
2 CRPV - Centre Régional de Pharmacovigilance
3 HEGP - Hôpital Européen Georges Pompidou [APHP]
4 UB - Université de Bordeaux
5 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
6 IThEM - U1140 - Innovations thérapeutiques en hémostase
7 UPD5 - Université Paris Descartes - Paris 5
8 USPC - Université Sorbonne Paris Cité
9 Service d'hématologie A [CHU HEGP]
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02044161
Contributor : Ghislaine Calvez <>
Submitted on : Thursday, February 21, 2019 - 12:30:43 PM
Last modification on : Thursday, April 11, 2019 - 4:02:54 PM

Identifiers

  • HAL Id : hal-02044161, version 1

Collections

UNIV-BREST | GETBO | UNIV-PARIS5 | IBSAM | USPC

Citation

Albert Trinh-Duc, Agnès Lillo-Le Louët, Éric Tellier, Thibault Viard, Grégoire Le Gal, et al.. Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database. Thrombosis Research, Elsevier, 2016, 146 (9), pp.43-45. ⟨hal-02044161⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

43

Contact

CCSD